Caxton Associates LLP Sells 548,559 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Caxton Associates cut its Gilead Sciences stake by 99.7% in the first quarter, selling 548,559 shares and retaining just 1,441 shares valued at approximately $201,000. Institutional investors overall still own 83.67% of Gilead’s stock.
• Analysts maintain a generally positive outlook, with 25 Buy ratings and four Holds producing a “Moderate Buy” consensus and an average price target of $157.93, above the stock’s reported $132.73 price.
• Gilead exceeded quarterly expectations with $2.03 in EPS and $6.96 billion in revenue, while revenue grew 4.4% year over year. However, analysts cited potential second-quarter earnings declines, cell-therapy competition and hepatitis C threats as risks.

Caxton Associates LLP lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 99.7% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,441 shares of the biopharmaceutical company's stock after selling 548,559 shares during the quarter. Caxton Associates LLP's holdings in Gilead Sciences were worth $201,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Paulson Wealth Management Inc. lifted its holdings in shares of Gilead Sciences by 1.8% during the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company's stock valued at $477,000 after purchasing an additional 67 shares during the last quarter. Essex Financial Services Inc. grew its stake in shares of Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company's stock worth $948,000 after buying an additional 71 shares during the last quarter. Davidson Trust Co. increased its position in Gilead Sciences by 4.1% during the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company's stock valued at $262,000 after buying an additional 74 shares in the last quarter. Alpha Cubed Investments LLC raised its stake in Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company's stock valued at $812,000 after buying an additional 75 shares during the last quarter. Finally, Personal CFO Solutions LLC boosted its holdings in Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company's stock worth $561,000 after acquiring an additional 76 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on GILD. Truist Financial cut their target price on Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a research note on Tuesday, July 7th. HSBC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Cantor Fitzgerald reissued an "overweight" rating on shares of Gilead Sciences in a research report on Wednesday. Citigroup lifted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a "buy" rating in a report on Monday, April 13th. Finally, The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a "neutral" rating in a research note on Friday, April 17th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $157.93.

Gilead Sciences Stock Down 1.2%

GILD stock opened at $132.73 on Thursday. The stock has a market capitalization of $164.79 billion, a P/E ratio of 18.08 and a beta of 0.32. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The business has a fifty day moving average price of $129.68 and a 200-day moving average price of $135.84.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion for the quarter, compared to analysts' expectations of $6.91 billion. During the same period last year, the firm posted $1.81 earnings per share. Gilead Sciences's revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: UBS analyst Michael Yee reiterated a Buy rating and maintained a $175 price target, citing Gilead’s long-acting HIV pipeline and advances in pre-exposure prophylaxis (PrEP) as sources of durable growth. Michael Yee Reiterates Buy on Gilead
• Positive Sentiment: The earnings preview highlights continued strength in Gilead’s HIV franchise, rising expectations for Yeztugo, and progress in oncology. These businesses could help support revenue growth and investor sentiment if management provides constructive guidance. Gilead to Report Q2 Earnings
• Neutral Sentiment: Gilead’s CAR-T therapies remain established products, but off-the-shelf developers are targeting market segments that approved therapies do not fully address. This could expand the broader CAR-T market while also increasing competitive pressure over time. BMS and Gilead Rule in the CAR-T Space
• Negative Sentiment: Barclays lowered its Gilead price target from $155 to $145 and assigned an Equal Weight rating, signaling more limited near-term upside despite the target remaining above the current trading level. Barclays Gilead Price Target Update
• Negative Sentiment: Analyst previews warn that Gilead may report a decline in second-quarter earnings and does not appear to have the usual combination of positive earnings revisions and estimate-beat indicators. Competitive pressure in Cell Therapy is an additional concern heading into the report. Analysts Estimate Gilead to Report a Decline in Earnings
• Negative Sentiment: Atea Pharmaceuticals said its hepatitis C combination therapy matched Gilead’s drug in a pivotal Phase 3 trial. If approved, a competing oral regimen could threaten Gilead’s hepatitis C franchise, although commercialization and regulatory risks remain. Atea Hepatitis C Phase 3 Trial

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 15,000 shares of the business's stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the transaction, the chief executive officer directly owned 617,567 shares of the company's stock, valued at $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 67,000 shares of company stock worth $8,687,140. Company insiders own 0.30% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.